Addiction, PTSD and depression: high-burden conditions with large treatment gaps
Solvonis develops psychedelic-based medicines where the need is greatest. We start with alcohol use disorder, where we are building a franchise across the UK, Europe and the U.S., and extend the approach to stimulant use disorder, PTSD and depression with anhedonia.
AUD is a large, underserved market
Worldwide, only 1 in 6 people with AUD receive treatment. Solvonis is building an AUD franchise on one mechanism, with two products and two regulatory pathways.
SVN-001 is developed for severe AUD in the UK and Europe. SVN-002, an esketamine oral thin film (OTF), is developed for moderate-to-severe AUD in the U.S.
Epidemiological estimates, not treated or addressable patients; thresholds differ by region, so the two figures are not additive. UK and EU4 (France, Germany, Italy, Spain): Company estimates (July 2026) of DSM-5 severe AUD, ages 15+, from WHO Europe, Degenhardt et al. (Addiction 2019), Eurostat 2024 and ONS mid-2024 population data. U.S.: SAMHSA, 2024 NSDUH, Tables 5.2A and 5.2B, ages 12+, civilian non-institutionalised; components rounded. Treatment rate: Mekonen et al., Addiction 2021.
of U.S. overdose deaths (January 2021 to June 2024) involved stimulants.
Source: Tanz et al., MMWR 2025.
No FDA-approved medicine for cocaine or methamphetamine addiction
SVN-015 is a new dopamine and serotonin reuptake inhibitor. It is being evaluated by the U.S. National Institute on Drug Abuse (NIDA), which funds and conducts the studies while Solvonis retains ownership and intellectual property.
Initial NIDA-funded screening was encouraging, and SVN-015 has advanced into further NIDA-funded studies.
SVN-015 for stimulant use disorderMDMA-assisted therapy has generated clinical interest; delivery at scale is the challenge
MDMA is not proprietary, and supervised treatment is resource-intensive. SVN-114 is a preclinical, proprietary entactogen designed for healthcare delivery, not simply another MDMA analogue.
SVN-114 for PTSDRetain the therapeutically relevant serotonergic profile while designing around MDMA’s limitations.
SVN-114 is preclinical; intended advantages remain to be established. Sources: Mitchell et al., Nat Med 2023; FDA Psychopharmacologic Drugs Advisory Committee, 4 June 2024; Company programme data.
Anhedonia is an unmet need
Anhedonia, the loss of pleasure and motivation, is a core symptom of major depressive disorder (MDD). Many patients do not achieve adequate symptom control on selective serotonin reuptake inhibitors (SSRIs).
SVN-015 is a serotonin-dopamine reuptake inhibitor, designed to engage pathways involved in mood, motivation and reward. It is a second programme from the same molecule as SVN-015 for StUD.
SVN-015 for depressionPharma is paying for psychedelic and rapid-acting neuropsychiatry assets, including Lilly’s acquisition of AtaiBeckley (lead in depression, completed September 2026) and AbbVie’s acquisition of Gilgamesh’s bretisilocin (Phase 2 MDD asset, October 2025).
See the transactionsSVN-015 is preclinical. Preclinical animal data do not establish human safety or efficacy in depression. Sources: Eli Lilly, 11 September 2026; AbbVie, 17 October 2025. Sector context; not valuation comparables.